TERN Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several promising small-molecule candidates designed to address these complex metabolic conditions. Among its key programs is TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist that is currently undergoing Phase IIa clinical trials. TERN-101 aims to target NASH through a mechanism distinct from bile acid modulation, potentially offering a novel approach to this challenging liver disease.
Terns Pharmaceuticals is also advancing TERN-201, a vascular adhesion protein-1 (VAP-1) inhibitor that is in Phase Ib clinical trials for NASH. This candidate is designed to disrupt the inflammatory processes associated with NASH by inhibiting VAP-1, a protein involved in immune cell trafficking and liver inflammation. Additionally, the company is developing TERN-501, a thyroid hormone receptor beta (THR-β) agonist with enhanced liver distribution and metabolic stability, which is currently in Phase I clinical trials for NASH.
Another significant component of Terns' pipeline is TERN-601, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist program. TERN-601 is designed for oral administration and targets both NASH and metabolic diseases such as obesity. This program leverages the GLP-1 receptor pathway, known for its role in glucose regulation and weight management, to offer a potentially effective treatment for these conditions.
Incorporated in 2016 and headquartered in Foster City, California, Terns Pharmaceuticals, Inc. has positioned itself at the forefront of developing next-generation therapies for liver and metabolic diseases. The company's focus on small-molecule agents reflects its commitment to advancing treatment options for conditions with significant unmet medical needs, utilizing innovative approaches to address the underlying mechanisms of NASH and obesity.
|
